<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biosci Microbiota Food Health</journal-id><journal-id journal-id-type="iso-abbrev">Biosci Microbiota Food Health</journal-id><journal-id journal-id-type="publisher-id">BMFH</journal-id><journal-title-group><journal-title>Bioscience of Microbiota, Food and Health</journal-title></journal-title-group><issn pub-type="ppub">2186-6953</issn><issn pub-type="epub">2186-3342</issn><publisher><publisher-name>BMFH Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27867803</article-id><article-id pub-id-type="pmc">5107634</article-id><article-id pub-id-type="publisher-id">2016-002</article-id><article-id pub-id-type="doi">10.12938/bmfh.2016-002</article-id><article-categories><subj-group subj-group-type="heading"><subject>Full Paper</subject></subj-group></article-categories><title-group><article-title>Effect of <italic>Bifidobacterium animalis</italic> ssp. <italic>lactis</italic> GCL2505 on visceral fat accumulation in healthy Japanese adults: a
randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>TAKAHASHI</surname><given-names>Shota</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref rid="cor1" ref-type="corresp"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>ANZAWA</surname><given-names>Daisuke</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>TAKAMI</surname><given-names>Kazuyo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>ISHIZUKA</surname><given-names>Akihiro</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>MAWATARI</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>KAMIKADO</surname><given-names>Kohei</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>SUGIMURA</surname><given-names>Haruhi</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>NISHIJIMA</surname><given-names>Tomohiko</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1"><label>1</label>Institute of Health Sciences, Ezaki Glico Co., Ltd., 2-14-1 Musashino, Akishima-shi, Tokyo 196-0021, Japan</aff><aff id="aff2"><label>2</label>Institute of Health Sciences, Ezaki Glico Co., Ltd., 4-6-5 Utajima Nishiyodogawa, Osaka 555-8502, Japan</aff><aff id="aff3"><label>3</label>Medical Corporation Shinkokai C&#x02019;est lavie Shimbashi Clinic, 2-39-3 Nishishimbashi, Minato-ku, Tokyo 105-0003, Japan</aff></contrib-group><author-notes><corresp id="cor1">*Corresponding author. Shota Takahashi, Institute of Health Sciences, Ezaki Glico Co., Ltd., 2-14-1 Musashino, Akishima-shi, Tokyo 196-0021,
Japan. Phone: +81-042-544-2231; Fax: +81-042-545-9202; E-mail: <email xlink:href="takahashi-shota@glico.co.jp">takahashi-shota@glico.co.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="ppub"><year>2016</year></pub-date><volume>35</volume><issue>4</issue><fpage>163</fpage><lpage>171</lpage><history><date date-type="received"><day>29</day><month>1</month><year>2016</year></date><date date-type="accepted"><day>06</day><month>5</month><year>2016</year></date></history><permissions><copyright-statement>BMFH Press</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License.
</license-p></license></permissions><abstract><p><italic>Bifidobacterium animalis</italic> ssp. <italic>lactis</italic> GCL2505 (<italic>B. lactis</italic> GCL2505) is able to survive passage through the
intestine and then proliferate, leading to an increase in the amount of gut bifidobacteria. In the present study, we evaluated the impact of <italic>B.
lactis</italic> GCL2505 on abdominal visceral fat storage in overweight and mildly obese Japanese adults. This clinical study was a double-blind, randomized,
placebo-controlled, parallel-group comparative trial performed for 12 weeks. Healthy Japanese subjects (N=137) with body mass indices ranging from 23 to 30
kg/m<sup>2</sup> consumed either fermented milk containing <italic>B. lactis</italic> GCL2505 or a placebo every day, and then visceral and subcutaneous
abdominal fat areas were measured by computed tomography as the primary endpoints. The number of fecal bifidobacteria was also measured. Visceral fat area, but
not subcutaneous fat area, was significantly reduced from baseline at 8 and 12 weeks in the GCL2505 group, compared with the placebo group. The total number of
fecal bifidobacteria was significantly increased in the GCL2505 group. These results indicate that <italic>B. lactis</italic> GCL2505 reduces abdominal visceral
fat, a key factor associated with metabolic disorders. This finding suggests that this probiotic strain can potentially serve as a specific functional food to
achieve visceral fat reduction in overweight or mildly obese individuals.</p></abstract><kwd-group><kwd>probiotics</kwd><kwd><italic>Bifidobacterium</italic></kwd><kwd>visceral fat</kwd><kwd>randomized trial</kwd><kwd>overweight</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>Abdominal visceral fat accumulation is a known underlying component of metabolic syndrome (MS), which is an independent risk factor for coronary heart disease,
hypertension, type-2 diabetes, and impaired glucose tolerance [<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref>]. Visceral fat accumulation is a form of obesity related to environmental factors such
as diet and physical inactivity [<xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r6" ref-type="bibr">6</xref>].</p><p>Although inappropriate dietary habits and inadequate physical activity are the main causes of overweight, obesity, and excess accumulation of abdominal visceral
fat, several other environmental factors, including gut microbiota, are also being recognized as important factors [<xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r8" ref-type="bibr">8</xref>]. The human intestinal tract harbors a large, active, and complex community of microorganisms comprising over 500 different
taxa and 100 trillion cells [<xref rid="r9" ref-type="bibr">9</xref>]. The gut microbiota plays important roles in digestion, metabolism, nutrient extraction,
vitamin synthesis, prevention of colonization by pathogens, and immunomodulation [<xref rid="r9" ref-type="bibr">9</xref>]. In addition to an increased energy
harvest from the diet, several other mechanisms, including lipopolysaccharide-induced chronic inflammation, modulation of tissue fatty acid composition, and gut
hormone secretion, have been proposed as links between the gut microbiota and obesity [<xref rid="r10" ref-type="bibr">10</xref>].</p><p>Attention has recently focused on the association between the composition of the microbiota, especially the
<italic>Firmicutes</italic>/<italic>Bacteroidetes</italic> ratio, and obesity [<xref rid="r11" ref-type="bibr">11</xref>, <xref rid="r12" ref-type="bibr">12</xref>]. Furthermore, <italic>Bifidobacterium</italic> (phylum <italic>Actinobacteria</italic>) has also been implicated in obesity and overweight [<xref rid="r13" ref-type="bibr">13</xref>]. For instance, the number of bifidobacteria in feces is lower in overweight and obese subjects than in lean subjects [<xref rid="r13" ref-type="bibr">13</xref>]. These findings suggest that an increase in gut bifidobacteria elicits beneficial effects on obesity, overweight, and
metabolic disorders. Thus, probiotics that include bifidobacteria have been reported to exert beneficial effects on weight loss, lowering fat mass, and
improvement of the insulin sensitivity in most animal studies and in some human studies [<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r18" ref-type="bibr">18</xref>]. A systematic review
of probiotics for weight loss and glycemic control indicated that probiotics were effective for improvement of glycemic control, but have limited efficacy in
terms of decreasing body weight and body mass index (BMI) in humans [<xref rid="r17" ref-type="bibr">17</xref>, <xref rid="r18" ref-type="bibr">18</xref>]. Until
now, however, there have been only limited human studies on abdominal visceral fat.</p><p>The probiotic species <italic>B. animalis</italic> ssp. <italic>lactis</italic> (<italic>B. lactis</italic>), which is used widely as a daily product, has been
reported to have a large number of health benefits for gastrointestinal and immune function [<xref rid="r16" ref-type="bibr">16</xref>, <xref rid="r19" ref-type="bibr">19</xref>, <xref rid="r20" ref-type="bibr">20</xref>]. <italic>B. lactis</italic> GCL2505 originated from the healthy human gut and is used in
fermented milk products in the Japanese market. We previously showed that <italic>B. lactis</italic> GCL2505 reaches the intestine in a viable form and
subsequently proliferates to increase the total number of gut bifidobacteria [<xref rid="r21" ref-type="bibr">21</xref>, <xref rid="r22" ref-type="bibr">22</xref>].</p><p>The purpose of this study was to examine the effects of probiotic <italic>B. lactis</italic> GCL2505 on abdominal fat storage, especially abdominal visceral fat,
in overweight or mildly obese Japanese adults (BMI: 23&#x02013;30 kg/m<sup>2</sup>).</p></sec><sec sec-type="methods" id="s2"><title>MATERIALS AND METHODS</title><sec><title>Study design</title><p>This study was a multicenter, randomized, double-blind, placebo-controlled intervention trial that was conducted according to the Consolidated Standards of
Reporting Trials (CONSORT) statement [<xref rid="r23" ref-type="bibr">23</xref>]. The study was also conducted in accordance with the Declaration of Helsinki,
and the protocol was approved by the Institutional Review Board of C&#x02019;est Lavie Shimbashi Clinic (Tokyo, Japan). Subjects provided written informed consent
before study initiation. This study was performed by a contract research organization, KSO Co., Ltd. (Tokyo, Japan), from December 2014 to June 2015 at the
following two facilities in Tokyo, Japan: C&#x02019;est Lavie Shimbashi Clinic and Oval Coat Kenshin Clinic. The principle investigator of this study was one of the
authors, Haruhi Sugimura, M.D.</p></sec><sec><title>Subjects</title><p>Healthy Japanese participants were recruited based on their age (20&#x02013;65 years) and BMI (23&#x02013;30 kg/m<sup>2</sup>) and were categorized as overweight and obesity
according to World Health Organization standards [<xref rid="r24" ref-type="bibr">24</xref>]. Subjects had not received medications that would interfere with
the results and had no serious diseases, including hepatic, cardiovascular, respiratory, endocrine, or metabolic disorders. Other exclusion criteria were as
follows: 1) food allergy; 2) antibiotic use within 4 weeks before entering the study; 3) use of supplements that would interfere with the results; 4) pregnancy,
lactation, or planning to become pregnant; 5) participation in another clinical study; and 6) unsuitable for computed tomography (CT) (e.g., metal devices in
the body). The subjects were considered to be healthy by the principle investigator based on the results of blood and urine tests and subjects&#x02019; self-reports.
Subjects were asked to maintain their normal lifestyle and to avoid any other probiotic-containing products during the study.</p></sec><sec><title>Probiotic fermented milk</title><p>The test product was fermented milk (FM) containing <italic>B. lactis</italic> GCL2505 (approximately 8 &#x000d7; 10<sup>10</sup> colony forming units [cfu]/100 g),
which was not combined with any other starter cultures. The FM was delivered to each subject weekly under refrigeration and stored in a refrigerator until
consumption to maintain the number of viable <italic>B. lactis</italic> GCL2505 cells. The placebo was prepared with the same ingredients and by adding
food-grade acetic acid and lactic acid to adjust its pH to 4.5 without any starter cultures. The FM and placebo had the same nutritional content and flavor.
They both consisted of approximately 9% skim milk powder, sweeteners, and a small amount of flavoring, and they were identical in terms of energy (44 kcal),
protein (3.0 g), fat (0.1 g), carbohydrate (7.7 g), sodium (54 mg), and calcium (96 mg) content per 100 g. The number of viable <italic>B. lactis</italic>
GCL2505 cells was determined using a transoligosaccharide propionate agar medium (Yakult Pharmaceutical Industry Co., Ltd., Tokyo, Japan).</p></sec><sec><title>Study protocol</title><p>The study period consisted of a 2-week screening, followed by a 12-week treatment period. During the screening period, each subject was assessed with regard to
the eligibility criteria. Randomization was carried out by a study statistician not directly involved in the trial. All of the 160 eligible subjects were
randomly allocated to two groups defined as the GCL2505 and placebo groups, matching them for age, sex, body weight, BMI, and visceral fat area, according to
information obtained during the screening period. The linkage between the identification number and treatment group was kept in a sealed document by the
allocation officer. The investigators, subjects, and study statistician had no knowledge of the treatment groups until data analyses were complete.</p><p>Each subject consumed 100 g FM or placebo every day for 12 weeks. They were instructed to maintain their regular lifestyle and to keep a daily record of FM or
placebo consumption, diet, and number of steps walked as the amount of physical activity. Abdominal CT scans for the measurement of abdominal fat area were
conducted at 0, 8, and 12 weeks. Anthropometry and fasting blood, urine, and fecal sampling were performed at 0, 4, 8, and 12 weeks. Fecal samples were
delivered to the laboratory in a refrigerated, anaerobic state using an AnaeroPack Kenki (Mitsubishi GAS Chemical Co., Inc., Tokyo, Japan). These samples were
diluted 10-fold with phosphate-buffered saline (pH 7.4) and homogenized. Suspensions were kept at &#x02212;80&#x000b0;C until required for analysis.</p></sec><sec><title>Anthropometric measures and body composition</title><p>Weight and height were measured to the nearest 0.1 kg and 0.1 cm, respectively, with the subject standing. BMI was calculated in the standard way: weight (kg)
divided by the square of height (m). Waist and hip circumferences were measured to the nearest 0.1 cm in a standing position. Waist circumference was measured
around the abdomen at the level of the umbilicus. Hip circumference was measured at the level of maximum extension of the buttocks posteriorly in a horizontal
plane.</p></sec><sec><title>Abdominal fat area</title><p>The abdominal visceral fat area (VFA) and subcutaneous fat area (SFA) were measured using CT. Four-slice CT images (120 kVp, 200 mAs tube current, 8.0 mm slice
thickness, and 430 mm field of view) were acquired at the level of the lumbar 4&#x02013;5 vertebrae. Abdominal VFA, SFA, and total (the sum of visceral and
subcutaneous) fat area (TFA) were measured using the Fat Scan ver. 4 software (East Japan Institute of Technology Co., Ltd., Hitachi, Ibaraki, Japan). To avoid
unnecessary radiation exposure, CT scans were conducted only once at each measurement point (0, 8, and 12 weeks). The measurement of VFA by CT is reportedly
easily affected by the respiration phase in subjects and the slice site [<xref rid="r25" ref-type="bibr">25</xref>]. Therefore, to investigate the time course
changes of VFA accurately in the present study, the scanner and principal investigator strictly assessed a series of CT images obtained from the same subjects
at each measurement point and excluded any inappropriate data.</p></sec><sec><title>Biochemical parameters</title><p>The concentrations of several plasma biochemical parameters were measured at 0, 4, 8, and 12 weeks. Blood was drawn from each subject in a fasting state, in
which they had consumed no food or drink except water for at least 10 hours. Biochemical parameters, including total cholesterol, high-density lipoprotein
cholesterol, low-density lipoprotein cholesterol, triglycerides, free fatty acid, albumin, aspartate transaminase, alanine aminotransaminase, lactate
dehydrogenase, bilirubin, alkaline phosphatase, &#x003b3;-GTP, creatine phosphokinase, white blood cells, red blood cells, hemoglobin, platelets, fasting blood glucose,
hemoglobin A1c, total protein, uric nitrogen, creatinine, uric acid, sodium, chloride, potassium, calcium, inorganic phosphorus, magnesium, and serum iron were
analyzed by LSI Medience Corporation (Tokyo, Japan). The values of urine parameters were measured at 0, 4, 8, and 12 weeks. Urine parameters, including urine
protein, sugar, urobilinogen, bilirubin, ketone bodies, and occult blood, were also analyzed by LSI Medience Corporation.</p></sec><sec><title>Gut bifidobacteria</title><p>Bacterial DNA was extracted from 10-fold dilutions of fecal samples, and the number of gut bifidobacteria was subsequently quantified by real-time PCR using
<italic>Bifidobacterium</italic> species- and subspecies-specific primers according to the procedure previously described [<xref rid="r21" ref-type="bibr">21</xref>]. Total counts of bifidobacteria in the fecal samples were represented as the sum of nine species (<italic>B. bifidum, B. breve, B. longum, B.
adolescentis, B. angulatum, B. catenulatum, B. dentium, B. infantis,</italic> and <italic>B. lactis</italic>). The detection limit of each bifidobacteria
species or subspecies was 2.0 &#x000d7; 10<sup>5</sup> cells per gram of feces.</p></sec><sec><title>Statistical analysis</title><p>Results were expressed in either actual values or changes from 0 week. Unpaired t-tests (two-sided) were used to compare baseline characteristics of the
subjects in the two groups, and calculated p-values &#x0003c;0.05 were considered statistically significant. An intergroup comparison by two-factor repeated-measures
analysis of variance (ANOVA) was performed using the actual values. Interactions of group by time were considered significant for p<italic>-</italic>values
&#x0003c;0.05. Bonferroni&#x02019;s correction was used for <italic>post hoc</italic> comparisons when ANOVA revealed statistically significant differences.</p><p>All statistical analyses were performed using the IBM SPSS Statistics for Windows software version 21 (IBM Corp., Armonk, NY, USA).</p></sec></sec><sec sec-type="results" id="s3"><title>RESULTS</title><sec><title>Characteristics of subjects</title><p>Participant flow is shown in <xref ref-type="fig" rid="fig_001">Fig. 1</xref><fig orientation="portrait" fig-type="figure" id="fig_001" position="float"><label>Fig. 1.</label><caption><p>Flow diagram of the study showing numbers of participants.</p></caption><graphic xlink:href="bmfh-35-163-g001"/></fig>. Subjects (N=160) were randomly assigned to the GCL2505 and placebo groups. One subject in the placebo group did not complete the study due to bone
fracture. At 0 week, CT was not obtained for another subject due to interference of barium for the contrast X-ray; therefore, this subject was excluded from the
analysis (due to protocol violation). From the viewpoint of the accuracy of the CT data as described in the Materials and Methods (<italic>abdominal fat
area</italic>), we assessed a series of CT images obtained from the same subjects at each measurement point to exclude any inappropriate data. Fourteen
subjects (7 in the GCL2505 group and 7 in the placebo group) were excluded due to overestimation of VFA mainly caused by compression of the abdominal cavity
during inspiration, and 7 subjects (3 in the GCL2505 group and 4 in the placebo group) were excluded due to underestimation of VFA mainly caused by the
inclusion of an internal organ or gas in the CT scan images. Consequently, 10 subjects in the GCL2505 group and 11 subjects in the placebo group were excluded
from the analysis. Thus, the numbers of subjects for analysis were 137 (69 in the GCL2505 group and 68 in the placebo group). There were no significant
differences in baseline data between the GCL2505 and placebo groups (<xref rid="tbl_001" ref-type="table">Table 1</xref><table-wrap id="tbl_001" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Baseline characteristics of the subjects</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">GCL2505</th><th align="center" rowspan="1" colspan="1">Placebo</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Subjects (N)</td><td align="center" rowspan="1" colspan="1">69</td><td align="center" rowspan="1" colspan="1">68</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">41</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">27</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">46.9 &#x000b1; 8.8</td><td align="center" rowspan="1" colspan="1">46.9 &#x000b1; 8.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="center" rowspan="1" colspan="1">167.0 &#x000b1; 8.5</td><td align="center" rowspan="1" colspan="1">166.6 &#x000b1; 8.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="center" rowspan="1" colspan="1">75.0 &#x000b1; 8.4</td><td align="center" rowspan="1" colspan="1">74.9 &#x000b1; 8.6</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">26.8 &#x000b1; 1.5</td><td align="center" rowspan="1" colspan="1">26.9 &#x000b1; 1.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist circumference (cm)</td><td align="center" rowspan="1" colspan="1">93.0 &#x000b1; 4.8</td><td align="center" rowspan="1" colspan="1">92.9 &#x000b1; 3.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Hip circumference (cm)</td><td align="center" rowspan="1" colspan="1">98.4 &#x000b1; 3.4</td><td align="center" rowspan="1" colspan="1">98.3 &#x000b1; 3.2</td></tr><tr><td align="left" rowspan="1" colspan="1">WHR</td><td align="center" rowspan="1" colspan="1">0.95 &#x000b1; 0.04</td><td align="center" rowspan="1" colspan="1">0.94 &#x000b1; 0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">Visceral fat area (cm<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">133.4 &#x000b1; 29.6</td><td align="center" rowspan="1" colspan="1">124.3 &#x000b1; 26.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Subcutaneous fat area (cm<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">215.9 &#x000b1; 55.8</td><td align="center" rowspan="1" colspan="1">219.9 &#x000b1; 43.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Total fat area (cm<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">349.3 &#x000b1; 60.5</td><td align="center" rowspan="1" colspan="1">344.2 &#x000b1; 45.9</td></tr></tbody></table><table-wrap-foot><p>Values are means &#x000b1; SD. BMI: Body Mass Index; WHR: waist to hip ratio.</p><p>p-values were analyzed by unpaired t-test.</p></table-wrap-foot></table-wrap>) and in nutrient intake (dietary energy, protein, carbohydrate, and fat) and steps walked during the treatment period (<xref rid="tbl_002" ref-type="table">Table 2</xref><table-wrap id="tbl_002" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Daily nutrition intake and steps walked in the GCL2505-supplemented (N=69) and placebo (N=68) groups during the treatment period</title></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" rowspan="3" align="left"/><th colspan="8" align="center" rowspan="1">Treatment period<hr/></th></tr><tr><th colspan="2" align="center" rowspan="1">0 week<hr/></th><th colspan="2" align="center" rowspan="1">4 weeks<hr/></th><th colspan="2" align="center" rowspan="1">8 weeks<hr/></th><th colspan="2" align="center" rowspan="1">12 weeks<hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="2" colspan="1">Energy (kcal/day)</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">1,817</td><td align="center" valign="top" rowspan="1" colspan="1">1,715, 1,919</td><td align="center" valign="top" rowspan="1" colspan="1">1,853</td><td align="center" valign="top" rowspan="1" colspan="1">1,737, 1,968</td><td align="center" valign="top" rowspan="1" colspan="1">1,818</td><td align="center" valign="top" rowspan="1" colspan="1">1,706, 1,931</td><td align="center" valign="top" rowspan="1" colspan="1">1,845</td><td align="center" valign="top" rowspan="1" colspan="1">1,724, 1,966</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">1,876</td><td align="center" valign="top" rowspan="1" colspan="1">1,768, 1,984</td><td align="center" valign="top" rowspan="1" colspan="1">1,909</td><td align="center" valign="top" rowspan="1" colspan="1">1,789, 2,029</td><td align="center" valign="top" rowspan="1" colspan="1">1,914</td><td align="center" valign="top" rowspan="1" colspan="1">1,812, 2,016</td><td align="center" valign="top" rowspan="1" colspan="1">1,881</td><td align="center" valign="top" rowspan="1" colspan="1">1,787, 1,974</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Protein (g/day)</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">68.6</td><td align="center" valign="top" rowspan="1" colspan="1">64.3, 72.9</td><td align="center" valign="top" rowspan="1" colspan="1">69.3</td><td align="center" valign="top" rowspan="1" colspan="1">65.0, 73.5</td><td align="center" valign="top" rowspan="1" colspan="1">68.3</td><td align="center" valign="top" rowspan="1" colspan="1">63.8, 72.9</td><td align="center" valign="top" rowspan="1" colspan="1">69.0</td><td align="center" valign="top" rowspan="1" colspan="1">64.5, 73.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">70.8</td><td align="center" valign="top" rowspan="1" colspan="1">66.5, 75.0</td><td align="center" valign="top" rowspan="1" colspan="1">71.0</td><td align="center" valign="top" rowspan="1" colspan="1">67.0, 75.0</td><td align="center" valign="top" rowspan="1" colspan="1">72.1</td><td align="center" valign="top" rowspan="1" colspan="1">67.6, 76.6</td><td align="center" valign="top" rowspan="1" colspan="1">71.8</td><td align="center" valign="top" rowspan="1" colspan="1">68.2, 75.5</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Carbohydrate (g/day)</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">241.1</td><td align="center" valign="top" rowspan="1" colspan="1">228.0, 254.2</td><td align="center" valign="top" rowspan="1" colspan="1">242.3</td><td align="center" valign="top" rowspan="1" colspan="1">226.3, 258.4</td><td align="center" valign="top" rowspan="1" colspan="1">241.0</td><td align="center" valign="top" rowspan="1" colspan="1">226.1, 255.9</td><td align="center" valign="top" rowspan="1" colspan="1">241.7</td><td align="center" valign="top" rowspan="1" colspan="1">224.5, 258.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">252.9</td><td align="center" valign="top" rowspan="1" colspan="1">237.5, 268.3</td><td align="center" valign="top" rowspan="1" colspan="1">249.8</td><td align="center" valign="top" rowspan="1" colspan="1">232.0, 267.7</td><td align="center" valign="top" rowspan="1" colspan="1">251.9</td><td align="center" valign="top" rowspan="1" colspan="1">236.4, 267.4</td><td align="center" valign="top" rowspan="1" colspan="1">247.6</td><td align="center" valign="top" rowspan="1" colspan="1">231.9, 263.3</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Fat (g/day)</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">57.2</td><td align="center" valign="top" rowspan="1" colspan="1">52.7, 61.8</td><td align="center" valign="top" rowspan="1" colspan="1">60.9</td><td align="center" valign="top" rowspan="1" colspan="1">56.2, 65.6</td><td align="center" valign="top" rowspan="1" colspan="1">58.4</td><td align="center" valign="top" rowspan="1" colspan="1">53.6, 63.1</td><td align="center" valign="top" rowspan="1" colspan="1">60.2</td><td align="center" valign="top" rowspan="1" colspan="1">55.0, 65.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">58.6</td><td align="center" valign="top" rowspan="1" colspan="1">54.2, 62.9</td><td align="center" valign="top" rowspan="1" colspan="1">63.7</td><td align="center" valign="top" rowspan="1" colspan="1">57.6, 69.8</td><td align="center" valign="top" rowspan="1" colspan="1">62.4</td><td align="center" valign="top" rowspan="1" colspan="1">58.4, 66.4</td><td align="center" valign="top" rowspan="1" colspan="1">60.9</td><td align="center" valign="top" rowspan="1" colspan="1">57.1, 64.7</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Steps walked (counts/day)</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">7,206</td><td align="center" valign="top" rowspan="1" colspan="1">6,552, 7,861</td><td align="center" valign="top" rowspan="1" colspan="1">7,681</td><td align="center" valign="top" rowspan="1" colspan="1">6,933, 8,430</td><td align="center" valign="top" rowspan="1" colspan="1">7,696</td><td align="center" valign="top" rowspan="1" colspan="1">6,870, 8,522</td><td align="center" valign="top" rowspan="1" colspan="1">7,831</td><td align="center" valign="top" rowspan="1" colspan="1">7,049, 8,613</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">7,754</td><td align="center" valign="top" rowspan="1" colspan="1">6,835, 8,674</td><td align="center" valign="top" rowspan="1" colspan="1">8,175</td><td align="center" valign="top" rowspan="1" colspan="1">7,080, 9,271</td><td align="center" valign="top" rowspan="1" colspan="1">8,264</td><td align="center" valign="top" rowspan="1" colspan="1">7,200, 9,328</td><td align="center" valign="top" rowspan="1" colspan="1">8,048</td><td align="center" valign="top" rowspan="1" colspan="1">7,037, 9,058</td></tr></tbody></table><table-wrap-foot><p>Values are means and 95% confidence intervals (CIs).</p></table-wrap-foot></table-wrap>). The intake rates were 99.5% and 99.8% for FM (GCL2505 group) and the placebo (placebo group), respectively. No adverse events were observed
throughout this study in any subjects with regard to safety parameters including blood and urine tests.</p></sec><sec><title>Abdominal fat area</title><p>Changes in VFA, SFA, and TFA are summarized in <xref rid="tbl_003" ref-type="table">Table 3</xref><table-wrap id="tbl_003" orientation="portrait" position="float"><label>Table 3.</label><caption><title>Changes in abdominal fat areas by computed tomography scan in the GCL2505-supplemented (N=69) and placebo (N=68) groups during the treatment
period</title></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3" rowspan="3" align="left"/><th colspan="6" align="center" rowspan="1">Treatment period<hr/></th><th rowspan="3" align="center" colspan="1">Time &#x000d7; group <sup>a</sup></th></tr><tr><th colspan="2" align="center" rowspan="1">0 week<hr/></th><th colspan="2" align="center" rowspan="1">8 weeks<hr/></th><th colspan="2" align="center" rowspan="1">12 weeks<hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">VFA (cm<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">Actual values</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">133.4</td><td align="center" valign="top" rowspan="1" colspan="1">126.4, 140.4</td><td align="center" valign="top" rowspan="1" colspan="1">127.3</td><td align="center" valign="top" rowspan="1" colspan="1">120.0, 134.6</td><td align="center" valign="top" rowspan="1" colspan="1">128.3</td><td align="center" valign="top" rowspan="1" colspan="1">121.2, 135.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">124.3</td><td align="center" valign="top" rowspan="1" colspan="1">118.0, 130.6</td><td align="center" valign="top" rowspan="1" colspan="1">125.2</td><td align="center" valign="top" rowspan="1" colspan="1">118.5, 132.0</td><td align="center" valign="top" rowspan="1" colspan="1">125.8</td><td align="center" valign="top" rowspan="1" colspan="1">119.3, 132.3</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Change from 0 week</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;6.8<sup>##</sup></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;10.6, &#x02212;2.9</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;5.1<sup>#</sup></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;8.6, &#x02212;1.5</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.9</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;2.6, 4.4</td><td align="center" valign="top" rowspan="1" colspan="1">1.5</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.3, 4.3</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SFA (cm<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">Actual values</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">215.9</td><td align="center" valign="top" rowspan="1" colspan="1">202.7, 229.0</td><td align="center" valign="top" rowspan="1" colspan="1">213.7</td><td align="center" valign="top" rowspan="1" colspan="1">200.9, 226.6</td><td align="center" valign="top" rowspan="1" colspan="1">214.8</td><td align="center" valign="top" rowspan="1" colspan="1">201.7, 227.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.676</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">219.9</td><td align="center" valign="top" rowspan="1" colspan="1">209.5, 230.2</td><td align="center" valign="top" rowspan="1" colspan="1">216.0</td><td align="center" valign="top" rowspan="1" colspan="1">204.9, 227.1</td><td align="center" valign="top" rowspan="1" colspan="1">219.8</td><td align="center" valign="top" rowspan="1" colspan="1">208.6, 231.0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Change from 0 week</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;2.4</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;5.9, 1.2</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.1</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;5.2, 3.0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;3.9</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;7.6, &#x02212;0.1</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.1</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;3.8, 3.6</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TFA (cm<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">Actual values</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">349.3</td><td align="center" valign="top" rowspan="1" colspan="1">335.0, 363.5</td><td align="center" valign="top" rowspan="1" colspan="1">341.0</td><td align="center" valign="top" rowspan="1" colspan="1">326.6, 355.5</td><td align="center" valign="top" rowspan="1" colspan="1">343.1</td><td align="center" valign="top" rowspan="1" colspan="1">328.8, 357.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.111</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">344.2</td><td align="center" valign="top" rowspan="1" colspan="1">333.3, 355.1</td><td align="center" valign="top" rowspan="1" colspan="1">341.2</td><td align="center" valign="top" rowspan="1" colspan="1">329.2, 353.3</td><td align="center" valign="top" rowspan="1" colspan="1">345.6</td><td align="center" valign="top" rowspan="1" colspan="1">333.4, 357.7</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Change from 0 week</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;9.1</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;14.2, &#x02212;4.0</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;6.2</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;11.9, &#x02212;0.5</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;3.0</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;8.4, 2.5</td><td align="center" valign="top" rowspan="1" colspan="1">1.4</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;3.6, 6.4</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>Values are means and 95% confidence intervals (CIs). VFA: visceral fat area; SFA: subcutaneous fat area; TFA: total fat area.</p><p>There was a significant difference between the groups, as determined using an unpaired t-test with Bonferroni correction. <sup>#</sup>p&#x0003c;0.05;
<sup>##</sup>p&#x0003c;0.01.</p><p><sup>a</sup>p-value represented as a group-by-time interaction effect by two-factor repeated-measures ANOVA using actual values.</p></table-wrap-foot></table-wrap>. There was a significant group by time interaction in VFA from baseline. The mean decreases in VFA at 8 and 12 weeks from baseline were
significantly greater in the GCL2505 group (&#x02212;6.8 cm<sup>2</sup> [95% confidence interval (CI), &#x02212;10.6 to &#x02212;2.9], &#x02212;5.1 cm<sup>2</sup> [&#x02212;8.6 to &#x02212;1.5]) than in the
placebo group (0.9 cm<sup>2</sup> [&#x02212;2.6 to 4.4], 1.5 cm<sup>2</sup> [&#x02212;1.3 to 4.3]). In addition, the mean TFA tended to decrease from baseline in the GCL2505
group compared with the placebo group at 12 weeks (p=0.050). There were no statistically significant differences in SFA between the two groups and no changes
within either group.</p><p><xref rid="tbl_004" ref-type="table">Table 4</xref><table-wrap id="tbl_004" orientation="portrait" position="float"><label>Table 4.</label><caption><title>Changes in abdominal fat areas in subjects classified as non-MS by computed tomography in the GCL2505-supplemented (N=59) and placebo (N=54) groups
during the treatment period</title></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3" rowspan="3" align="left"/><th colspan="6" align="center" rowspan="1">Treatment period <hr/></th><th rowspan="3" align="center" colspan="1">Time &#x000d7; group <sup>a</sup></th></tr><tr><th colspan="2" align="center" rowspan="1">0 week<hr/></th><th colspan="2" align="center" rowspan="1">8 weeks<hr/></th><th colspan="2" align="center" rowspan="1">12 weeks<hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">VFA (cm<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">Actual values</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">131.6</td><td align="center" valign="top" rowspan="1" colspan="1">123.7, 139.5</td><td align="center" valign="top" rowspan="1" colspan="1">125.4</td><td align="center" valign="top" rowspan="1" colspan="1">117.2, 133.5</td><td align="center" valign="top" rowspan="1" colspan="1">125.2</td><td align="center" valign="top" rowspan="1" colspan="1">117.3, 133.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">120.2</td><td align="center" valign="top" rowspan="1" colspan="1">113.9, 126.6</td><td align="center" valign="top" rowspan="1" colspan="1">121.5</td><td align="center" valign="top" rowspan="1" colspan="1">114.3, 128.7</td><td align="center" valign="top" rowspan="1" colspan="1">122.4</td><td align="center" valign="top" rowspan="1" colspan="1">115.7, 129.2</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Change from 0 week</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;7.0<sup>##</sup></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;10.9, &#x02212;3.1</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;6.4<sup>##</sup></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;10.2, &#x02212;2.7</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.2</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;2.6, 5.1</td><td align="center" valign="top" rowspan="1" colspan="1">2.2</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.0, 5.4</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SFA (cm<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">Actual values</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">217.5</td><td align="center" valign="top" rowspan="1" colspan="1">203.1, 232.0</td><td align="center" valign="top" rowspan="1" colspan="1">216.6</td><td align="center" valign="top" rowspan="1" colspan="1">202.5, 230.8</td><td align="center" valign="top" rowspan="1" colspan="1">217.0</td><td align="center" valign="top" rowspan="1" colspan="1">202.6, 231.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.497</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">227.6</td><td align="center" valign="top" rowspan="1" colspan="1">216.1, 239.0</td><td align="center" valign="top" rowspan="1" colspan="1">223.6</td><td align="center" valign="top" rowspan="1" colspan="1">211.4, 235.9</td><td align="center" valign="top" rowspan="1" colspan="1">227.0</td><td align="center" valign="top" rowspan="1" colspan="1">214.6, 239.3</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Change from 0 week</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.2</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;5.1, 2.7</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.6</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;5.1, 3.9</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;3.9</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;8.4, 0.5</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.6</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;4.9, 3.7</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TFA (cm<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">Actual values</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">349.2</td><td align="center" valign="top" rowspan="1" colspan="1">333.7, 364.6</td><td align="center" valign="top" rowspan="1" colspan="1">342.0</td><td align="center" valign="top" rowspan="1" colspan="1">326.6, 357.4</td><td align="center" valign="top" rowspan="1" colspan="1">342.1</td><td align="center" valign="top" rowspan="1" colspan="1">326.7, 357.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.108</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">347.8</td><td align="center" valign="top" rowspan="1" colspan="1">335.4, 360.2</td><td align="center" valign="top" rowspan="1" colspan="1">345.1</td><td align="center" valign="top" rowspan="1" colspan="1">331.3, 358.9</td><td align="center" valign="top" rowspan="1" colspan="1">349.4</td><td align="center" valign="top" rowspan="1" colspan="1">335.5, 363.3</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Change from 0 week</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;8.2</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;13.8, &#x02212;2.6</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;7.0</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;13.4, &#x02212;0.7</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;2.7</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;9.1, 3.7</td><td align="center" valign="top" rowspan="1" colspan="1">1.6</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;4.3, 7.5</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>Non-MS was defined as subjects without metabolic syndrome having high visceral fat area (&#x02265;100 cm<sup>2</sup>) and two or more of the following criteria:
1) triglyceride &#x02265;150 mg and/or HDL-cholesterol &#x0003c;40 mg/dl, 2) fasting blood glucose &#x02265;110 mg/dl and 3) systolic blood pressure &#x02265;130 mmHg and/or diastolic
blood pressure &#x02265;85 mmHg.</p><p>Values are means and 95% confidence intervals (CIs). VFA: visceral fat area; SFA: subcutaneous fat area; TFA: total fat area.</p><p>There was a significant difference between the groups, as determined using an unpaired t-test with Bonferroni correction. <sup>##</sup>p&#x0003c;0.01.</p><p><sup>a</sup>p-value represented as a group-by-time interaction effect by two-factor repeated-measures ANOVA using actual values.</p></table-wrap-foot></table-wrap> shows changes in abdominal fat area in subjects classified as non-MS (59 in the GCL2505 group and 54 in the placebo group), defined as not having
a high visceral fat area (&#x02265;100 cm<sup>2</sup>) and two or more of the following criteria according to the diagnostic criteria for MS in Japan: 1) triglycerides
&#x02265;150 mg/dl and/or HDL cholesterol &#x0003c;40 mg/dl; 2) fasting blood glucose &#x02265;110 mg/dl; and 3) systolic blood pressure &#x02265;130 mmHg and/or diastolic blood pressure
&#x02265;85 mmHg. The mean decreases in VFA at 8 and 12 weeks from baseline were also significantly greater in the GCL2505 group than in the placebo group in non-MS
subjects. Furthermore, the mean TFA also tended to decrease from baseline in the GCL2505 group compared with the placebo group at 12 weeks (p=0.053).</p></sec><sec><title>Anthropometric parameters</title><p><xref rid="tbl_005" ref-type="table">Table 5</xref><table-wrap id="tbl_005" orientation="portrait" position="float"><label>Table 5.</label><caption><title>Changes in anthropometric parameters in the GCL2505-supplemented (N=69) and placebo (N=68) groups during the treatment period</title></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" rowspan="3" align="left"/><th colspan="8" align="center" rowspan="1">Treatment period <hr/></th><th rowspan="3" align="center" colspan="1">Time &#x000d7; group <sup>a</sup></th></tr><tr><th colspan="2" align="center" rowspan="1">0 week <hr/></th><th colspan="2" align="center" rowspan="1">4 weeks <hr/></th><th colspan="2" align="center" rowspan="1">8 weeks <hr/></th><th colspan="2" align="center" rowspan="1">12 weeks <hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Weight (kg)</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">75.0</td><td align="center" valign="top" rowspan="1" colspan="1">73.1, 77.0</td><td align="center" valign="top" rowspan="1" colspan="1">75.5</td><td align="center" valign="top" rowspan="1" colspan="1">73.5, 77.6</td><td align="center" valign="top" rowspan="1" colspan="1">75.2</td><td align="center" valign="top" rowspan="1" colspan="1">73.2, 77.2</td><td align="center" valign="top" rowspan="1" colspan="1">75.0</td><td align="center" valign="top" rowspan="1" colspan="1">72.9, 77.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.772</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">74.9</td><td align="center" valign="top" rowspan="1" colspan="1">72.8, 76.9</td><td align="center" valign="top" rowspan="1" colspan="1">75.5</td><td align="center" valign="top" rowspan="1" colspan="1">73.5, 77.5</td><td align="center" valign="top" rowspan="1" colspan="1">75.0</td><td align="center" valign="top" rowspan="1" colspan="1">73.0, 77.0</td><td align="center" valign="top" rowspan="1" colspan="1">74.8</td><td align="center" valign="top" rowspan="1" colspan="1">72.8, 76.8</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">26.8</td><td align="center" valign="top" rowspan="1" colspan="1">26.5, 27.2</td><td align="center" valign="top" rowspan="1" colspan="1">27.0</td><td align="center" valign="top" rowspan="1" colspan="1">26.6, 27.4</td><td align="center" valign="top" rowspan="1" colspan="1">26.9</td><td align="center" valign="top" rowspan="1" colspan="1">26.5, 27.3</td><td align="center" valign="top" rowspan="1" colspan="1">26.8</td><td align="center" valign="top" rowspan="1" colspan="1">26.4, 27.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.731</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">26.9</td><td align="center" valign="top" rowspan="1" colspan="1">26.5, 27.3</td><td align="center" valign="top" rowspan="1" colspan="1">27.2</td><td align="center" valign="top" rowspan="1" colspan="1">26.8, 27.5</td><td align="center" valign="top" rowspan="1" colspan="1">27.0</td><td align="center" valign="top" rowspan="1" colspan="1">26.6, 27.3</td><td align="center" valign="top" rowspan="1" colspan="1">26.9</td><td align="center" valign="top" rowspan="1" colspan="1">26.5, 27.3</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WHR</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">0.95</td><td align="center" valign="top" rowspan="1" colspan="1">0.94, 0.95</td><td align="center" valign="top" rowspan="1" colspan="1">0.95</td><td align="center" valign="top" rowspan="1" colspan="1">0.94, 0.96</td><td align="center" valign="top" rowspan="1" colspan="1">0.95</td><td align="center" valign="top" rowspan="1" colspan="1">0.94, 0.96</td><td align="center" valign="top" rowspan="1" colspan="1">0.95</td><td align="center" valign="top" rowspan="1" colspan="1">0.94, 0.96</td><td align="center" valign="top" rowspan="1" colspan="1">0.807</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">0.94</td><td align="center" valign="top" rowspan="1" colspan="1">0.94, 0.95</td><td align="center" valign="top" rowspan="1" colspan="1">0.95</td><td align="center" valign="top" rowspan="1" colspan="1">0.94, 0.96</td><td align="center" valign="top" rowspan="1" colspan="1">0.95</td><td align="center" valign="top" rowspan="1" colspan="1">0.94, 0.96</td><td align="center" valign="top" rowspan="1" colspan="1">0.95</td><td align="center" valign="top" rowspan="1" colspan="1">0.94, 0.96</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>Values are means and 95% confidence intervals (CIs). WHR: waist to hip ratio.</p><p><sup>a</sup>p-value represented as a group-by-time interaction effect using two-factor repeated-measures ANOVA.</p></table-wrap-foot></table-wrap> shows the anthropometric data. There were no statistically significant differences in body weight, BMI, or waist to hip ratio between the two
groups.</p></sec><sec><title>Biochemical parameters</title><p>There were no statistically significant differences in any of the plasma or urine biochemical parameters throughout the study between the two groups (data not
shown).</p></sec><sec><title>Gut bifidobacteria</title><p>Changes in fecal bifidobacteria are presented in <xref rid="tbl_006" ref-type="table">Table 6</xref><table-wrap id="tbl_006" orientation="portrait" position="float"><label>Table 6.</label><caption><title>Changes in fecal bifidobacteria in the GCL2505-supplemented (N=69) and placebo (N=68) groups during the treatment period</title></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" rowspan="3" align="left"/><th colspan="8" align="center" rowspan="1">Treatment period <hr/></th><th rowspan="3" align="center" colspan="1">Time &#x000d7; group <sup>a</sup></th></tr><tr><th colspan="2" align="center" rowspan="1">0 week <hr/></th><th colspan="2" align="center" rowspan="1">4 weeks <hr/></th><th colspan="2" align="center" rowspan="1">8 weeks <hr/></th><th colspan="2" align="center" rowspan="1">12 weeks <hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>B. lactis </italic></td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">5.43</td><td align="center" valign="top" rowspan="1" colspan="1">5.29, 5.56</td><td align="left" valign="top" rowspan="1" colspan="1">8.96<sup>##</sup></td><td align="center" valign="top" rowspan="1" colspan="1">8.77, 9.16</td><td align="left" valign="top" rowspan="1" colspan="1">9.17<sup>##</sup></td><td align="center" valign="top" rowspan="1" colspan="1">9.02, 9.32</td><td align="left" valign="top" rowspan="1" colspan="1">9.33<sup>##</sup></td><td align="center" valign="top" rowspan="1" colspan="1">9.16, 9.49</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">5.48</td><td align="center" valign="top" rowspan="1" colspan="1">5.31, 5.64</td><td align="left" valign="top" rowspan="1" colspan="1">5.42</td><td align="center" valign="top" rowspan="1" colspan="1">5.28, 5.56</td><td align="left" valign="top" rowspan="1" colspan="1">5.37</td><td align="center" valign="top" rowspan="1" colspan="1">5.29, 5.45</td><td align="left" valign="top" rowspan="1" colspan="1">5.31</td><td align="center" valign="top" rowspan="1" colspan="1">5.30, 5.31</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total </td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">9.06</td><td align="center" valign="top" rowspan="1" colspan="1">8.79, 9.33</td><td align="left" valign="top" rowspan="1" colspan="1">9.60<sup>##</sup></td><td align="center" valign="top" rowspan="1" colspan="1">9.50, 9.71</td><td align="left" valign="top" rowspan="1" colspan="1">9.60<sup>##</sup></td><td align="center" valign="top" rowspan="1" colspan="1">9.46, 9.74</td><td align="left" valign="top" rowspan="1" colspan="1">9.76<sup>##</sup></td><td align="center" valign="top" rowspan="1" colspan="1">9.63, 9.88</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">bifidobacteria<sup> b</sup></td><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">9.07</td><td align="center" valign="top" rowspan="1" colspan="1">8.82, 9.31</td><td align="left" valign="top" rowspan="1" colspan="1">9.14</td><td align="center" valign="top" rowspan="1" colspan="1">8.89, 9.40</td><td align="left" valign="top" rowspan="1" colspan="1">9.13</td><td align="center" valign="top" rowspan="1" colspan="1">8.86, 9.41</td><td align="left" valign="top" rowspan="1" colspan="1">9.20</td><td align="center" valign="top" rowspan="1" colspan="1">8.93, 9.47</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Endogenous</td><td align="left" valign="top" rowspan="1" colspan="1">GCL2505</td><td align="center" valign="top" rowspan="1" colspan="1">9.05</td><td align="center" valign="top" rowspan="1" colspan="1">8.77, 9.32</td><td align="left" valign="top" rowspan="1" colspan="1">9.08</td><td align="center" valign="top" rowspan="1" colspan="1">8.83, 9.33</td><td align="left" valign="top" rowspan="1" colspan="1">8.94</td><td align="center" valign="top" rowspan="1" colspan="1">8.65, 9.22</td><td align="left" valign="top" rowspan="1" colspan="1">9.04</td><td align="center" valign="top" rowspan="1" colspan="1">8.76, 9.32</td><td align="center" valign="top" rowspan="1" colspan="1">0.271</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">bifidobacteria<sup> c </sup></td><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">9.04</td><td align="center" valign="top" rowspan="1" colspan="1">8.78, 9.29</td><td align="left" valign="top" rowspan="1" colspan="1">9.13</td><td align="center" valign="top" rowspan="1" colspan="1">8.88, 9.39</td><td align="left" valign="top" rowspan="1" colspan="1">9.11</td><td align="center" valign="top" rowspan="1" colspan="1">8.83, 9.40</td><td align="left" valign="top" rowspan="1" colspan="1">9.19</td><td align="center" valign="top" rowspan="1" colspan="1">8.92, 9.47</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>Values are means and 95% confidence intervals (CIs) of common logarithms of the number of bacteria per 1 g feces.</p><p>There was a significant difference between the groups, as determined using an unpaired t-test with Bonferroni correction. <sup>#</sup>p&#x0003c;0.05;
<sup>##</sup>p&#x0003c;0.01.</p><p><sup>a </sup>p-value represented as a group-by-time interaction effect using two-factor repeated-measures ANOVA.</p><p><sup>b </sup>Total bifidobacteria are expressed as the sum of the counts of nine species (<italic>B. bifidum, B. breve, B. longum, B. adolescentis, B.
angulatum, B. catenulatum, B. dentium, B. infantis</italic>, and <italic>B. lactis</italic>).</p><p><sup>c </sup>Endogenous bifidobacteria are expressed as the counts of total bifidobacteria excluding <italic>B. lactis</italic>.</p></table-wrap-foot></table-wrap>. There were significant group by time interactions in the total number of bifidobacteria and <italic>B. lactis</italic> cells. At 4 weeks, the
total number of bifidobacteria significantly increased in the GCL2505 group compared with the placebo group, and this difference was maintained during the study
period. Similarly, the number of <italic>B. lactis</italic> cells significantly increased in feces after 4 weeks of <italic>B. lactis</italic> GCL2505
ingestion, and this difference was maintained until 12 weeks. However, the levels of other endogenous bifidobacteria (<italic>B. bifidum, B. breve, B. longum,
B. adolescentis, B. angulatum, B. catenulatum, B. dentium,</italic> and <italic>B. infantis</italic>) were not significantly different between the two
groups.</p></sec></sec><sec sec-type="discussion" id="s4"><title>DISCUSSION</title><p>FM containing 10<sup>10</sup> cfu of <italic>B. lactis</italic> GCL2505 was given to healthy overweight or mildly obese Japanese adults, and its effects on the
amount of abdominal fat, especially visceral fat, were investigated. The results of this study showed that VFA was significantly decreased in the GCL2505 group
compared with the placebo group at 8 and 12 weeks. Abdominal visceral fat accumulation is affected by exercise and food intake [<xref rid="r3" ref-type="bibr">3</xref>], but there were no significant differences in the daily number of steps walked or nutrient intake between the GCL2505 and placebo groups during the
study period. Therefore, the present results clearly demonstrate that <italic>B. lactis</italic> GCL2505 consumption decreases VFA. Other anthropometric
parameters such as SFA and body weight also did not change significantly, in agreement with a meta-analysis reported by Park <italic>et al.</italic> [<xref rid="r18" ref-type="bibr">18</xref>].</p><p>Several studies have shown that excess accumulation of visceral fat rather than increased body weight, BMI, or subcutaneous fat correlates with metabolic
disorders [<xref rid="r25" ref-type="bibr">25</xref>, <xref rid="r26" ref-type="bibr">26</xref>]. The visceral adipose tissue compartment is described as a unique
pathogenic fat depot [<xref rid="r6" ref-type="bibr">6</xref>] and as an endocrine organ that secretes various bioactive substances such as adipocytokines that
can influence the risk of developing metabolic disorders [<xref rid="r27" ref-type="bibr">27</xref>]. Additionally, although Asians including Japanese are less
obese, they tend to be more susceptible to metabolic disorders than Europeans and Americans [<xref rid="r28" ref-type="bibr">28</xref>]. Japanese men are also
reported to have a larger visceral adipose depot at the level of the waist circumference despite substantially less obesity overall [<xref rid="r28" ref-type="bibr">28</xref>]. Accordingly, in terms of preventing the development of metabolic disorders in Japanese adults, it is relatively more important to reduce
visceral fat rather than body weight or total body fat, and <italic>B. lactis</italic> GCL2505 may be useful for overweight and mildly obese adults.</p><p>Furthermore, the subjects in the present study with a BMI of 23&#x02013;30 kg/m<sup>2</sup> comprised both MS and non-MS subjects, as defined by the guidelines of the
Japanese committee organized to establish the definition and diagnostic criteria for MS in Japanese [<xref rid="r29" ref-type="bibr">29</xref>]. In analysis
stratified by the presence of MS, we also found that <italic>B. lactis</italic> GCL2505 consumption decreased VFA in non-MS subjects. Therefore, our present
results also suggest that <italic>B. lactis</italic> GCL2505 consumption may help to prevent progression to MS in non-MS individuals, which could reduce the risk
of MS-associated disorders such as type-2 diabetes and cardiovascular disease.</p><p>Meta-analysis of obesity-associated alterations in the gut microbiota has shown a consistent difference between obese and lean subjects [<xref rid="r11" ref-type="bibr">11</xref>]. Gut bifidobacteria could be a potential nutritional and pharmacological target for the prevention of overweight and excess fat storage.
This hypothesis has stimulated the performance of several studies investigating the effects of probiotic bifidobacteria on visceral fat in rodents [<xref rid="r30" ref-type="bibr">30</xref>,<xref rid="r31" ref-type="bibr">31</xref>,<xref rid="r32" ref-type="bibr">32</xref>]. For example, administration of
<italic>B. adolescentis</italic> increased gut bifidobacteria, which led to amelioration of visceral fat accumulation and insulin sensitivity in rats [<xref rid="r31" ref-type="bibr">31</xref>]. Supplementation with <italic>B. breve</italic> strain B-3 in mice was also shown to suppress the accumulation of
epididymal fat mass through an increase in the number of gut bifidobacteria [<xref rid="r32" ref-type="bibr">32</xref>]. Both of these reports demonstrated the
efficacy in rodents of supplementation with a specific strain of <italic>Bifidobacterium</italic> and suggested an association between increased gut
bifidobacteria and suppressed fat accumulation. In contrast, there are few clinical studies evaluating the efficacy of probiotic bifidobacteria on visceral fat in
humans. Minami <italic>et al.</italic> reported that consumption of <italic>B. breve</italic> B-3 reduced fat mass measured by a bioelectrical impedance method in
adults but did not reveal a change in visceral adipose tissue [<xref rid="r33" ref-type="bibr">33</xref>]. In the present study, we clearly demonstrated the
utility of probiotic bifidobacteria to reduce visceral fat in humans, as in previous animal studies [<xref rid="r30" ref-type="bibr">30</xref>,<xref rid="r31" ref-type="bibr">31</xref>,<xref rid="r32" ref-type="bibr">32</xref>].</p><p><italic>B. lactis</italic> GCL2505 can reach the intestine in a viable form and subsequently proliferate, leading to an increase in the number of gut
bifidobacteria [<xref rid="r21" ref-type="bibr">21</xref>, <xref rid="r22" ref-type="bibr">22</xref>]. The present study also showed that the total numbers of
fecal bifidobacteria (0 week, 9.06 log cells/g feces; 12 weeks, 9.76 log cells/g feces) and fecal <italic>B. lactis</italic> cells (0 week, 5.43 log cells/g
feces; 12 weeks, 9.33 log cells/g feces) were significantly increased in the GCL2505 group. Such significant differences in the total numbers of bifidobacteria
and <italic>B. lactis</italic> cells between the two groups were maintained from 4 weeks to 12 weeks. Previously, we found in a clinical study that <italic>B.
lactis</italic> GCL2505 increased the numbers of fecal bifidobacteria more effectively than non-proliferating bifidobacteria and lactic acid bacterial strains
[<xref rid="r22" ref-type="bibr">22</xref>]. Because several previous studies have shown that a higher abundance of gut bifidobacteria was associated with
suppressed excess accumulation of fat mass [<xref rid="r30" ref-type="bibr">30</xref>,<xref rid="r31" ref-type="bibr">31</xref>,<xref rid="r32" ref-type="bibr">32</xref>], we propose that increasing gut bifidobacteria via ingestion of <italic>B. lactis</italic> GCL2505 can play an effective role in reducing VFA.</p><p>In addition, <italic>B. lactis</italic> GCL2505 reportedly caused a significant increase of IgA production and mucin secretion in the murine gut when compared
with a type strain of a bifidobacterial species (<italic>B. longum</italic> JCM1217<sup>T</sup>), and the proliferation level of the administered bifidobacteria
in the intestine affected these physiological responses of the host [<xref rid="r34" ref-type="bibr">34</xref>]. IgA production and mucin secretion in the gut are
associated with effective intestinal barrier function. Cani <italic>et al.</italic> suggested that oligofructose improved gut barrier function by increasing gut
bifidobacteria and lowered plasma lipopolysaccharide levels, which may contribute to decreased adipose mass and the expression of pro-inflammatory markers in
adipose tissue [<xref rid="r35" ref-type="bibr">35</xref>]. Similarly, the effect of <italic>B. lactis</italic> 420 on fat mass reduction might be related to an
improvement in gut barrier function [<xref rid="r30" ref-type="bibr">30</xref>]. Improved gut barrier function might also be a mechanism underlying the reduction
in abdominal fat upon supplementation with <italic>B. lactis</italic> GCL2505. However, no studies have been able to explain fully the underlying association
between fat metabolism and gut bifidobacteria, especially in humans. The mechanism of action of <italic>B. lactis</italic> GCL2505 observed in the present study
is also not clear. Further studies are warranted to elucidate how this strain affects fat metabolism and storage.</p><p>In conclusion, the present results indicate that consumption of FM containing <italic>B. lactis</italic> GCL2505 reduces abdominal visceral fat, a key factor
associated with metabolic disorders. Therefore, the present findings suggest that a specific strain of <italic>B. lactis</italic> GCL2505 is safe and could be
useful for the reduction of abdominal visceral fat, and they support daily consumption of this proliferative bifidobacteria as a potential way to prevent
metabolic disorders in overweight or mildly obese individuals.</p></sec></body><back><ack><p>We are grateful to the subjects for their cooperation and participation in this study. S. Takahashi, D. Anzawa, K. Takami, A. Ishizuka, T. Mawatari, K. Kamikado,
and T. Nishijima are employees of Ezaki Glico Co., Ltd., which produces dairy products using <italic>B. lactis</italic> GCL2505.</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group><name><surname>Nikolopoulou</surname><given-names>A</given-names></name><name><surname>Kadoglou</surname><given-names>NP</given-names></name></person-group>
<year>2012</year>
<article-title>Obesity and metabolic syndrome as related to cardiovascular disease</article-title>. <source>Expert Rev
Cardiovasc Ther</source><volume> 10</volume>: <fpage>933</fpage>&#x02013;<lpage>939</lpage>. <pub-id pub-id-type="pmid">22908926</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group><name><surname>Oka</surname><given-names>R</given-names></name><name><surname>Kobayashi</surname><given-names>J</given-names></name><name><surname>Yagi</surname><given-names>K</given-names></name><name><surname>Tanii</surname><given-names>H</given-names></name><name><surname>Miyamoto</surname><given-names>S</given-names></name><name><surname>Asano</surname><given-names>A</given-names></name><name><surname>Hagishita</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name><name><surname>Moriuchi</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Katsuda</surname><given-names>S</given-names></name><name><surname>Kawashiri</surname><given-names>MA</given-names></name><name><surname>Nohara</surname><given-names>A</given-names></name><name><surname>Takeda</surname><given-names>Y</given-names></name><name><surname>Mabuchi</surname><given-names>H</given-names></name><name><surname>Yamagishi</surname><given-names>M</given-names></name></person-group>
<year>2008</year>
<article-title>Reassessment of the cutoff values of waist circumference and visceral fat area for identifying Japanese
subjects at risk for the metabolic syndrome</article-title>. <source>Diabetes Res Clin Pract</source><volume> 79</volume>:
<fpage>474</fpage>&#x02013;<lpage>481</lpage>. <pub-id pub-id-type="pmid">18031862</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group><name><surname>Wajchenberg</surname><given-names>BL</given-names></name></person-group>
<year>2000</year>
<article-title>Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome</article-title>.
<source>Endocr Rev</source><volume> 21</volume>: <fpage>697</fpage>&#x02013;<lpage>738</lpage>. <pub-id pub-id-type="pmid">11133069</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group><name><surname>Alberti</surname><given-names>KG</given-names></name><name><surname>Zimmet</surname><given-names>P</given-names></name><name><surname>Shaw</surname><given-names>J</given-names></name></person-group>
<year>2006</year>
<article-title>Metabolic syndrome&#x02014;a new world-wide definition. A Consensus Statement from the International Diabetes
Federation</article-title>. <source>Diabet Med</source><volume> 23</volume>: <fpage>469</fpage>&#x02013;<lpage>480</lpage>. <pub-id pub-id-type="pmid">16681555</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group><name><surname>Montague</surname><given-names>CT</given-names></name><name><surname>O&#x02019;Rahilly</surname><given-names>S</given-names></name></person-group>
<year>2000</year>
<article-title>The perils of portliness: causes and consequences of visceral adiposity</article-title>.
<source>Diabetes</source><volume> 49</volume>: <fpage>883</fpage>&#x02013;<lpage>888</lpage>. <pub-id pub-id-type="pmid">10866038</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group><name><surname>Fox</surname><given-names>CS</given-names></name><name><surname>Massaro</surname><given-names>JM</given-names></name><name><surname>Hoffmann</surname><given-names>U</given-names></name><name><surname>Pou</surname><given-names>KM</given-names></name><name><surname>Maurovich-Horvat</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>CY</given-names></name><name><surname>Vasan</surname><given-names>RS</given-names></name><name><surname>Murabito</surname><given-names>JM</given-names></name><name><surname>Meigs</surname><given-names>JB</given-names></name><name><surname>Cupples</surname><given-names>LA</given-names></name><name><surname>D&#x02019;Agostino</surname><given-names>RB</given-names><suffix>Sr</suffix></name><name><surname>O&#x02019;Donnell</surname><given-names>CJ</given-names></name></person-group>
<year>2007</year>
<article-title>Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in
the Framingham Heart Study</article-title>. <source>Circulation</source><volume> 116</volume>: <fpage>39</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="pmid">17576866</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group><name><surname>Moreno-Indias</surname><given-names>I</given-names></name><name><surname>Cardona</surname><given-names>F</given-names></name><name><surname>Tinahones</surname><given-names>FJ</given-names></name><name><surname>Queipo-Ortu&#x000f1;o</surname><given-names>MI</given-names></name><name><surname>Queipo-Ortu&#x000f1;o</surname><given-names>M</given-names></name></person-group>
<year>2014</year>
<article-title>Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus</article-title>.
<source>Front Microbiol</source><volume> 5</volume>: <fpage>190</fpage>. <pub-id pub-id-type="pmid">24808896</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group><name><surname>Musso</surname><given-names>G</given-names></name><name><surname>Gambino</surname><given-names>R</given-names></name><name><surname>Cassader</surname><given-names>M</given-names></name></person-group>
<year>2010</year>
<article-title>Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications
for metabolic disorders</article-title>. <source>Curr Opin Lipidol</source><volume> 21</volume>: <fpage>76</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="pmid">19915460</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group><name><surname>Sekirov</surname><given-names>I</given-names></name><name><surname>Russell</surname><given-names>SL</given-names></name><name><surname>Antunes</surname><given-names>LC</given-names></name><name><surname>Finlay</surname><given-names>BB</given-names></name></person-group>
<year>2010</year>
<article-title>Gut microbiota in health and disease</article-title>. <source>Physiol Rev</source><volume> 90</volume>:
<fpage>859</fpage>&#x02013;<lpage>904</lpage>. <pub-id pub-id-type="pmid">20664075</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group><name><surname>Musso</surname><given-names>G</given-names></name><name><surname>Gambino</surname><given-names>R</given-names></name><name><surname>Cassader</surname><given-names>M</given-names></name></person-group>
<year>2010</year>
<article-title>Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded?</article-title><source>Diabetes
Care</source><volume> 33</volume>: <fpage>2277</fpage>&#x02013;<lpage>2284</lpage>. <pub-id pub-id-type="pmid">20876708</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group><name><surname>Angelakis</surname><given-names>E</given-names></name><name><surname>Armougom</surname><given-names>F</given-names></name><name><surname>Million</surname><given-names>M</given-names></name><name><surname>Raoult</surname><given-names>D</given-names></name></person-group>
<year>2012</year>
<article-title>The relationship between gut microbiota and weight gain in humans</article-title>. <source>Future
Microbiol</source><volume> 7</volume>: <fpage>91</fpage>&#x02013;<lpage>109</lpage>. <pub-id pub-id-type="pmid">22191449</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group><name><surname>John</surname><given-names>K</given-names></name><name><surname>Daniel</surname><given-names>N</given-names></name><name><surname>Ruchi</surname><given-names>M</given-names></name></person-group>
<year>2012</year>
<article-title>Impact of the gut microbiota on the development of obesity: current concepts</article-title>. <source>Am J
Gastroenterol</source><issue>Suppl 1</issue>: <fpage>22</fpage>&#x02013;<lpage>27</lpage>.</mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group><name><surname>Schwiertz</surname><given-names>A</given-names></name><name><surname>Taras</surname><given-names>D</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>K</given-names></name><name><surname>Beijer</surname><given-names>S</given-names></name><name><surname>Bos</surname><given-names>NA</given-names></name><name><surname>Donus</surname><given-names>C</given-names></name><name><surname>Hardt</surname><given-names>PD</given-names></name></person-group>
<year>2010</year>
<article-title>Microbiota and SCFA in lean and overweight healthy subjects</article-title>. <source>Obesity (Silver
Spring)</source><volume> 18</volume>: <fpage>190</fpage>&#x02013;<lpage>195</lpage>. <pub-id pub-id-type="pmid">19498350</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group><name><surname>Delzenne</surname><given-names>NM</given-names></name><name><surname>Neyrinck</surname><given-names>AM</given-names></name><name><surname>B&#x000e4;ckhed</surname><given-names>F</given-names></name><name><surname>Cani</surname><given-names>PD</given-names></name></person-group>
<year>2011</year>
<article-title>Targeting gut microbiota in obesity: effects of prebiotics and probiotics</article-title>. <source>Nat Rev
Endocrinol</source><volume> 7</volume>: <fpage>639</fpage>&#x02013;<lpage>646</lpage>. <pub-id pub-id-type="pmid">21826100</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group><name><surname>Festi</surname><given-names>D</given-names></name><name><surname>Schiumerini</surname><given-names>R</given-names></name><name><surname>Eusebi</surname><given-names>LH</given-names></name><name><surname>Marasco</surname><given-names>G</given-names></name><name><surname>Taddia</surname><given-names>M</given-names></name><name><surname>Colecchia</surname><given-names>A</given-names></name></person-group>
<year>2014</year>
<article-title>Gut microbiota and metabolic syndrome</article-title>. <source>World J Gastroenterol</source><volume>
20</volume>: <fpage>16079</fpage>&#x02013;<lpage>16094</lpage>. <pub-id pub-id-type="pmid">25473159</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group><name><surname>Chiu</surname><given-names>YH</given-names></name><name><surname>Lin</surname><given-names>SL</given-names></name><name><surname>Tsai</surname><given-names>JJ</given-names></name><name><surname>Lin</surname><given-names>MY</given-names></name></person-group>
<year>2014</year>
<article-title>Probiotic actions on diseases: implications for therapeutic treatments</article-title>. <source>Food
Funct</source><volume> 5</volume>: <fpage>625</fpage>&#x02013;<lpage>634</lpage>. <pub-id pub-id-type="pmid">24549263</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group><name><surname>Ruan</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name></person-group>
<year>2015</year>
<article-title>Effect of probiotics on glycemic control: a systematic review and meta-analysis of randomized, controlled
trials</article-title>. <source>PLoS One</source><volume> 10</volume>: <fpage>e0132121</fpage>. <pub-id pub-id-type="pmid">26161741</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Bae</surname><given-names>JH</given-names></name></person-group>
<year>2015</year>
<article-title>Probiotics for weight loss: a systematic review and meta-analysis</article-title>. <source>Nutr
Res</source><volume> 35</volume>: <fpage>566</fpage>&#x02013;<lpage>575</lpage>. <pub-id pub-id-type="pmid">26032481</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group><name><surname>Gill</surname><given-names>HS</given-names></name><name><surname>Rutherfurd</surname><given-names>KJ</given-names></name><name><surname>Prasad</surname><given-names>J</given-names></name><name><surname>Gopal</surname><given-names>PK</given-names></name></person-group>
<year>2000</year>
<article-title>Enhancement of natural and acquired immunity by <italic>Lactobacillus rhamnosus</italic> (HN001),
<italic>Lactobacillus acidophilus</italic> (HN017) and <italic>Bifidobacterium lactis </italic>(HN019)</article-title>. <source>Br J Nutr</source><volume>
83</volume>: <fpage>167</fpage>&#x02013;<lpage>176</lpage>. <pub-id pub-id-type="pmid">10743496</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group><name><surname>Taipale</surname><given-names>T</given-names></name><name><surname>Pienih&#x000e4;kkinen</surname><given-names>K</given-names></name><name><surname>Isolauri</surname><given-names>E</given-names></name><name><surname>Larsen</surname><given-names>C</given-names></name><name><surname>Brockmann</surname><given-names>E</given-names></name><name><surname>Alanen</surname><given-names>P</given-names></name><name><surname>Jokela</surname><given-names>J</given-names></name><name><surname>S&#x000f6;derling</surname><given-names>E</given-names></name></person-group>
<year>2011</year>
<article-title><italic>Bifidobacterium animalis</italic> subsp. <italic>lactis</italic> BB-12 in reducing the risk of
infections in infancy</article-title>. <source>Br J Nutr</source><volume> 105</volume>: <fpage>409</fpage>&#x02013;<lpage>416</lpage>. <pub-id pub-id-type="pmid">20863419</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group><name><surname>Ishizuka</surname><given-names>A</given-names></name><name><surname>Tomizuka</surname><given-names>K</given-names></name><name><surname>Aoki</surname><given-names>R</given-names></name><name><surname>Nishijima</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>R</given-names></name><name><surname>Ushida</surname><given-names>K</given-names></name><name><surname>Mawatari</surname><given-names>T</given-names></name><name><surname>Ikeda</surname><given-names>T</given-names></name></person-group>
<year>2012</year>
<article-title>Effects of administration of <italic>Bifidobacterium animalis</italic> subsp. <italic>lactis</italic> GCL2505
on defecation frequency and bifidobacterial microbiota composition in humans</article-title>. <source>J Biosci Bioeng</source><volume> 113</volume>:
<fpage>587</fpage>&#x02013;<lpage>591</lpage>. <pub-id pub-id-type="pmid">22284965</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Takami</surname><given-names>K</given-names></name><name><surname>Nishijima</surname><given-names>T</given-names></name><name><surname>Aoki</surname><given-names>R</given-names></name><name><surname>Mawatari</surname><given-names>T</given-names></name><name><surname>Ikeda</surname><given-names>T</given-names></name></person-group>
<year>2015</year>
<article-title>Short- and long-term dynamics in the intestinal microbiota following ingestion of <italic>Bifidobacterium
animalis</italic> subsp. <italic>lactis</italic> GCL2505</article-title>. <source>Biosci Microbiota Food Health</source><volume> 34</volume>:
<fpage>77</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="pmid">26594607</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name></person-group>, CONSORT Group. <year>2011</year>
<article-title>CONSORT 2010 statement: updated guidelines for reporting parallel group randomised
trials</article-title>. <source>Int J Surg</source><volume> 9</volume>: <fpage>672</fpage>&#x02013;<lpage>677</lpage>. <pub-id pub-id-type="pmid">22019563</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group><name><surname>Barba</surname><given-names>C</given-names></name><name><surname>Cavalli-Sforza</surname><given-names>T</given-names></name><name><surname>Cutter</surname><given-names>J</given-names></name><name><surname>Darnton-Hill</surname><given-names>I</given-names></name><name><surname>Deurenberg</surname><given-names>P</given-names></name><name><surname>Deurenberg-Yap</surname><given-names>M</given-names></name><name><surname>Gill</surname><given-names>T</given-names></name></person-group>, WHO Expert Consultation. <year>2004</year>
<article-title>Appropriate body-mass index for Asian populations and its implications for policy and
intervention strategies</article-title>. <source>Lancet</source><volume> 363</volume>: <fpage>157</fpage>&#x02013;<lpage>163</lpage>. <pub-id pub-id-type="pmid">14726171</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group><name><surname>Ryo</surname><given-names>M</given-names></name><name><surname>Kishida</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Yoshizumi</surname><given-names>T</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Shimomura</surname><given-names>I</given-names></name></person-group>
<year>2014</year>
<article-title>Clinical significance of visceral adiposity assessed by computed tomography: a Japanese
perspective</article-title>. <source>World J Radiol</source><volume> 6</volume>: <fpage>409</fpage>&#x02013;<lpage>416</lpage>. <pub-id pub-id-type="pmid">25071881</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group><name><surname>Chaston</surname><given-names>TB</given-names></name><name><surname>Dixon</surname><given-names>JB</given-names></name></person-group>
<year>2008</year>
<article-title>Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss:
findings from a systematic review</article-title>. <source>Int J Obes</source><volume> 32</volume>: <fpage>619</fpage>&#x02013;<lpage>628</lpage>. </mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group><name><surname>Farb</surname><given-names>MG</given-names></name><name><surname>Gokce</surname><given-names>N</given-names></name><name><surname>Reynolds</surname><given-names>JV</given-names></name></person-group>
<year>2015</year>
<article-title>Visceral adiposopathy: a vascular perspective</article-title>. <source>Horm Mol Biol Clin
Investig</source><volume> 21</volume>: <fpage>125</fpage>&#x02013;<lpage>136</lpage>. </mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group><name><surname>Kadowaki</surname><given-names>T</given-names></name><name><surname>Sekikawa</surname><given-names>A</given-names></name><name><surname>Murata</surname><given-names>K</given-names></name><name><surname>Maegawa</surname><given-names>H</given-names></name><name><surname>Takamiya</surname><given-names>T</given-names></name><name><surname>Okamura</surname><given-names>T</given-names></name><name><surname>El-Saed</surname><given-names>A</given-names></name><name><surname>Miyamatsu</surname><given-names>N</given-names></name><name><surname>Edmundowicz</surname><given-names>D</given-names></name><name><surname>Kita</surname><given-names>Y</given-names></name><name><surname>Sutton-Tyrrell</surname><given-names>K</given-names></name><name><surname>Kuller</surname><given-names>LH</given-names></name><name><surname>Ueshima</surname><given-names>H</given-names></name></person-group>
<year>2006</year>
<article-title>Japanese men have larger areas of visceral adipose tissue than Caucasian men in the same levels of waist
circumference in a population-based study</article-title>. <source>Int J Obes</source><volume> 30</volume>: <fpage>1163</fpage>&#x02013;<lpage>1165</lpage>.
</mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group><name><surname>Matsuzawa</surname><given-names>Y</given-names></name></person-group>
<year>2005</year>
<article-title>Metabolic syndrome&#x02014;definition and diagnostic criteria in Japan</article-title>. <source>J Atheroscler
Thromb</source><volume> 12</volume>: <fpage>301</fpage>. <pub-id pub-id-type="pmid">16394611</pub-id></mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group><name><surname>Stenman</surname><given-names>LK</given-names></name><name><surname>Waget</surname><given-names>A</given-names></name><name><surname>Garret</surname><given-names>C</given-names></name><name><surname>Klopp</surname><given-names>P</given-names></name><name><surname>Burcelin</surname><given-names>R</given-names></name><name><surname>Lahtinen</surname><given-names>S</given-names></name></person-group>
<year>2014</year>
<article-title>Potential probiotic <italic>Bifidobacterium animalis</italic> ssp. <italic>lactis</italic> 420 prevents
weight gain and glucose intolerance in diet-induced obese mice</article-title>. <source>Benef Microbes</source><volume> 5</volume>:
<fpage>437</fpage>&#x02013;<lpage>445</lpage>. <pub-id pub-id-type="pmid">25062610</pub-id></mixed-citation></ref><ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>XF</given-names></name><name><surname>Wang</surname><given-names>RL</given-names></name></person-group>
<year>2012</year>
<article-title><italic>Bifidobacterium adolescentis</italic> supplementation ameliorates visceral fat accumulation and
insulin sensitivity in an experimental model of the metabolic syndrome</article-title>. <source>Br J Nutr</source><volume> 107</volume>:
<fpage>1429</fpage>&#x02013;<lpage>1434</lpage>. <pub-id pub-id-type="pmid">21914236</pub-id></mixed-citation></ref><ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group><name><surname>Kondo</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>JZ</given-names></name><name><surname>Satoh</surname><given-names>T</given-names></name><name><surname>Odamaki</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Sugahara</surname><given-names>H</given-names></name><name><surname>Yaeshima</surname><given-names>T</given-names></name><name><surname>Iwatsuki</surname><given-names>K</given-names></name><name><surname>Kamei</surname><given-names>A</given-names></name><name><surname>Abe</surname><given-names>K</given-names></name></person-group>
<year>2010</year>
<article-title>Antiobesity effects of <italic>Bifidobacterium breve</italic> strain B-3 supplementation in a mouse model
with high-fat diet-induced obesity</article-title>. <source>Biosci Biotechnol Biochem</source><volume> 74</volume>: <fpage>1656</fpage>&#x02013;<lpage>1661</lpage>.
<pub-id pub-id-type="pmid">20699581</pub-id></mixed-citation></ref><ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group><name><surname>Minami</surname><given-names>J</given-names></name><name><surname>Kondo</surname><given-names>S</given-names></name><name><surname>Yanagisawa</surname><given-names>N</given-names></name><name><surname>Odamaki</surname><given-names>T</given-names></name><name><surname>Xiao</surname><given-names>JZ</given-names></name><name><surname>Abe</surname><given-names>F</given-names></name><name><surname>Nakajima</surname><given-names>S</given-names></name><name><surname>Hamamoto</surname><given-names>Y</given-names></name><name><surname>Saitoh</surname><given-names>S</given-names></name><name><surname>Shimoda</surname><given-names>T</given-names></name></person-group>
<year>2015</year>
<article-title>Oral administration of <italic>Bifidobacterium breve </italic>B-3 modifies metabolic functions in adults with
obese tendencies in a randomised controlled trial</article-title>. <source>J Nutr Sci</source><volume> 4</volume>: <fpage>e17</fpage>. <pub-id pub-id-type="pmid">26090097</pub-id></mixed-citation></ref><ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group><name><surname>Aoki</surname><given-names>R</given-names></name><name><surname>Tsuchida</surname><given-names>S</given-names></name><name><surname>Arai</surname><given-names>Y</given-names></name><name><surname>Ohno</surname><given-names>K</given-names></name><name><surname>Nishijima</surname><given-names>T</given-names></name><name><surname>Mawatari</surname><given-names>T</given-names></name><name><surname>Mikami</surname><given-names>Y</given-names></name><name><surname>Ushida</surname><given-names>K</given-names></name></person-group>
<year>2016</year>
<article-title>Effect of <italic>Bifidobacterium animalis</italic> subsp. <italic>lactis</italic> GCL2505 on the
physiological function of intestine in a rat model</article-title>. <source>Food Sci Nutr</source>.</mixed-citation></ref><ref id="r35"><label>35</label><mixed-citation publication-type="journal"><person-group><name><surname>Cani</surname><given-names>PD</given-names></name><name><surname>Neyrinck</surname><given-names>AM</given-names></name><name><surname>Fava</surname><given-names>F</given-names></name><name><surname>Knauf</surname><given-names>C</given-names></name><name><surname>Burcelin</surname><given-names>RG</given-names></name><name><surname>Tuohy</surname><given-names>KM</given-names></name><name><surname>Gibson</surname><given-names>GR</given-names></name><name><surname>Delzenne</surname><given-names>NM</given-names></name></person-group>
<year>2007</year>
<article-title>Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice
through a mechanism associated with endotoxaemia</article-title>. <source>Diabetologia</source><volume> 50</volume>: <fpage>2374</fpage>&#x02013;<lpage>2383</lpage>.
<pub-id pub-id-type="pmid">17823788</pub-id></mixed-citation></ref></ref-list></back></article>